

Asthma diagnosis vs. analysis of anti-asthmatic prescriptions to identify asthma in children

Marina Bianchi, Antonio Clavenna, Marco Sequi, Maurizio Bonati

▶ To cite this version:

Marina Bianchi, Antonio Clavenna, Marco Sequi, Maurizio Bonati. Asthma diagnosis vs. analysis of anti-asthmatic prescriptions to identify asthma in children. European Journal of Clinical Pharmacology, 2011, 67 (9), pp.967-968. 10.1007/s00228-011-1033-4. hal-00682333

HAL Id: hal-00682333 https://hal.science/hal-00682333

Submitted on 25 Mar 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Asthma diagnosis vs analysis of anti-asthmatic prescriptions to identify asthma in children.

Anti-asthmatics, with antipyretics and antibiotics, are the most frequently prescribed drugs in paediatrics. The prevalence rate of anti-asthmatic use in children ranges between 5% and 26%, depending on a few methodological aspects such as setting, patient's age, year of the study period, and drugs considered [1]. For asthma, an analysis of drug prescriptions as a reliable proxy of chronic disease prevalence is therefore a matter of debate [2]. Furthermore, the control over asthma disease changes over time and drug therapy must then also be modified. However, although there are established standardised questionnaires, several studies have criticized the use of self-reported asthma as an accurate measure of asthma prevalence [3]. Since several countries have health care databases on prescriptions, strategies for estimating the prevalence of asthma, based on the analysis of anti-asthmatic drug prescriptions, were developed and proposed [2, 4-6] as alternative methods of assessing asthma prevalence in a population. A published attempt to validate estimations, based on drug prescription, confronting them with the paediatricians' diagnoses [7] is here replicated in a different setting and with different methodological criteria. According to a previously described approach [4], all paediatric prescriptions reimbursed by the National Health Service (NHS) and dispensed by the retail pharmacies of one of the 15 Local Health Units (LHU) in the Lombardy Region during 2008 for 5,733 children and adolescents 6-17 years old were considered. Subjects receiving at least one package of inhalatory short-acting β-agonists (SABA), non-SABA, or oral formulation of steroids were defined as potential asthmatics (PA). 294 PA patients (5.1%) were identified. A simple questionnaire was prepared and sent to twelve out of 138 family paediatricians working in one randomly selected LHU, who were in charge of a total of 294 of 2,378 patients identified as PA.

Paediatricians provided information on 243 asthmatic 6-17 old subjects and the matching we performed allowed us to calculate false positive and false negative subjects. In 67% of the case the diagnosis was made by the paediatrician only and in 33% of cases it was also confirmed by the allergologist or pneumologist. The ratio boys/girls was 2.4.

The overall prevalence of PA was slightly higher than the diagnosis made by the doctors (5.1 % versus 4.2 %) and the agreement between the diagnosis provided by the paediatrician and that estimated based on drug prescriptions was 73.2% (p < 0.001), ranging between 37.5 and 100.0%

(Table 1). The sensitivity (a patient identified as PA by the analysis of prescriptions received, but assigned a non-asthma diagnosis by the paediatrician) was 90.6 % (66.7-100.0), whereas specificity (a patient identified as non-PA by the analysis of prescriptions received, but assigned an asthma diagnosis by the paediatrician) was 98.0% (95.8-99.8). A specificity of 86 % and a sensitivity of 63% in identifying PA were reported in a study in which similar criteria were used [5].

In conclusion, some studies have found prescription data to be a reliable and valid source of chronic disease prevalence [8]. However, limitations of these data do exist. The main limit, in Italy, of these studies utilizing drug prescriptions, is the absence of details on prescriptions (i.e. diagnosis and dose of medication). However, anti-asthmatic drugs are all reimbursed by the Italian NHS, so, unlike other studies, we were able to exclude underestimations due to lower income children. Furthermore, the rate of children treated by private doctors, and who were therefore excluded in our data, is very low. Therefore, these findings will support the use of this strategy in future studies on paediatric population-based drug use surveillance and research and analysis of adherence to international guidelines in treatment choices.

The authors are very grateful to the participating paediatricians: Bigalli L, Brivio L, Brunelli G, Corbetta D, Curto S, Di Cosimo ME, Di Pietro ME, Elli P, Gussoni C, Narducci M, Rabbone ML, Torrieri MC, and Zanetto F.

References

1. Bianchi M, Clavenna A, Bonati M (2010) Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000–2009 period. Eur J Clin Pharmacol 66:929–936

2. Hoffmann F and Glaeske G (2010) Prescriptions as a proxy for asthma in children: a good choice? Eur J Clin Pharmacol 66:307–313

3. Smeeton NC, Rona RJ, Oyarzun M, Diaz PV (2006) Agreement between responses to a standardized asthma questionnaire and a questionnaire following a demonstration of asthma symptoms in adults. Am J Epidemiol 163:384–391

4. Bianchi M, Clavenna A, Labate L, Bortolotti A, Fortino I, Merlino L, Walter Locatelli G, Giuliani G, Bonati M (2009) Anti-asthmatic drug prescriptions to an Italian paedriatic population. Pediatr Allergy Immunol 20: 585–591

5. Moth G, Vedsted P, Schiøtz PO(2007) Identification of asthmatic children using prescription data and diagnosis Eur J Clin Pharmacol 63:605–611

6.Clavenna A, Rossi E, Berti A, Pedrazzi G, De Rosa M, Bonati M, and the ARNO Working Group (2003) Inappropriate use of anti-asthmatic drugs in the Italian paediatric population. Eur J Clin Pharmacol 59: 565–569

7. To T, Dell S, Dick PT, Cicutto L, Harris JK, MacLusky IB, Tassoudji M (2006) Case verification of children with asthma in Ontario. Pediatr Allergy Immunol 17: 69–76

8. Cox ER, Halloran DR, Homan SM, Welliver S, Mager DE (2008) Trends in the prevalence of chronic medication use in children: 2002–2005 Pediatrics 122:1053–1061

| | Subjects | | | | | | False | False |
|---------------|-----------|-----------|-----------|-------------|-------------|-------------|----------|----------|
| Paediatrician | with | Estimated | Agreement | Kappa | Sensitivity | Specificity | positive | negative |
| | asthma | PA | (%) | (95% CI) | (%) | (%) | (%) | (%) |
| | diagnosis | subjets | | | | | | |
| | | | | 0.91 | | | | |
| 1 | 21 | 23 | 91.3 | (0.81-0.99) | 95.2 | 99.5 | 13.0 | 4.8 |
| | | | | 0.88 | | | | |
| 2 | 29 | 25 | 86.2 | (0.79-0.98) | 82.8 | 99.8 | 4.0 | 17.2 |
| | | | | 0.52 | | | | |
| 3 | 9 | 24 | 37.5 | (0.30-0.75) | 90.9 | 96.4 | 66.7 | 11.1 |
| | | | | 0.78 | | | | |
| 4 | 22 | 29 | 75.9 | (0.66-0.89) | 89.3 | 97.7 | 34.5 | 13.6 |
| | | | | 0.76 | | | | |
| 5 | 13 | 9 | 69.2 | (0.54-0.97) | 66.7 | 99.8 | 11.1 | 30.8 |
| | | | | 0.73 | | | | |
| 6 | 13 | 22 | 59.1 | (0.56-0.91) | 100.0 | 98.2 | 40.9 | 0.0 |
| | | | | 0.72 | | | | |
| 7 | 15 | 23 | 65.2 | (0.56-0.89) | 93.3 | 97.7 | 39.1 | 6.7 |
| | | | | 0.85 | | | | |
| 8 | 18 | 24 | 75.0 | (0.73-0.97) | 100.0 | 98.9 | 25.0 | 0.0 |
| | | | | 0.61 | | | | |
| 9 | 10 | 22 | 45.5 | (0.39-0.82) | 100.0 | 95.8 | 54.5 | 0.0 |
| | | | | 0.86 | | | | |
| 10 | 48 | 48 | 100.0 | (0.78-0.94) | 87.5 | 98.6 | 12.5 | 12.5 |
| | | | | 0.86 | | | | |
| 11 | 14 | 16 | 87.5 | (0.73-0.99) | 92.9 | 99.3 | 18.8 | 7.1 |
| | | | | 0.80 | | | | |
| 12 | 25 | 29 | 86.2 | (0.68-0.92) | 88.0 | 93.7 | 24.1 | 12.0 |
| | | | | 0.79 | | | | |
| Total | 243 | 294 | 73.2 | (0.75-0.83) | 90.6 | 98.0 | 28.7 | 9.7 |

Table 1. Comparison between diagnosed asthmatic patients and those identified by drug prescriptions